[go: up one dir, main page]

MX2008013728A - Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo. - Google Patents

Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo.

Info

Publication number
MX2008013728A
MX2008013728A MX2008013728A MX2008013728A MX2008013728A MX 2008013728 A MX2008013728 A MX 2008013728A MX 2008013728 A MX2008013728 A MX 2008013728A MX 2008013728 A MX2008013728 A MX 2008013728A MX 2008013728 A MX2008013728 A MX 2008013728A
Authority
MX
Mexico
Prior art keywords
group
salt
therapeutic agent
amino
alkyl ether
Prior art date
Application number
MX2008013728A
Other languages
English (en)
Inventor
Noboru Iwakami
Shigeki Marubuchi
Tomohiro Okuda
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of MX2008013728A publication Critical patent/MX2008013728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulga un agente que consta de un derivado de éter de alquil-benzotiofeno representado por la fórmula general que se describe abajo o una sal del mismo: (ver fórmula I) en donde R1 y R2 representan de manera independiente por lo menos uno de los grupos seleccionados de un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo, un grupo arilo, un grupo aralquilo, un grupo alcoxi, un grupo ariloxi, un grupo alquiltio, un grupo ariltio, un grupo alquenilo, un grupo alqueniloxi, un grupo alquilsulfonilo, un grupo carbamoilo, un grupo heterocíclico, un grupo amino, grupo hidroxilo, un grupo carboxilo, un grupo nitro, un grupo oxo y similares; R3 representa un grupo alquilamino que puede ser sustituido o un grupo amino o un grupo hidroxilo que se puede proteger; y m y n representan de manera independiente un número entero de 1 a 6. El agente es útil como inductor de neurogénesis o un agente terapéutico para neuropatía.
MX2008013728A 2006-04-26 2007-04-24 Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo. MX2008013728A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006122080 2006-04-26
PCT/JP2007/058841 WO2007125913A1 (ja) 2006-04-26 2007-04-24 アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤

Publications (1)

Publication Number Publication Date
MX2008013728A true MX2008013728A (es) 2009-01-07

Family

ID=38655439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013728A MX2008013728A (es) 2006-04-26 2007-04-24 Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo.

Country Status (20)

Country Link
US (1) US20090093453A1 (es)
EP (1) EP2011796B1 (es)
JP (2) JP5695293B2 (es)
KR (1) KR101374593B1 (es)
CN (1) CN101432280B (es)
AU (1) AU2007244409B2 (es)
BR (1) BRPI0710239A2 (es)
CA (1) CA2648898C (es)
CY (1) CY1115643T1 (es)
DK (1) DK2011796T3 (es)
ES (1) ES2518371T3 (es)
IL (1) IL194569A (es)
MX (1) MX2008013728A (es)
NO (1) NO342153B1 (es)
NZ (1) NZ571975A (es)
PL (1) PL2011796T3 (es)
PT (1) PT2011796E (es)
SI (1) SI2011796T1 (es)
WO (1) WO2007125913A1 (es)
ZA (1) ZA200808728B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60220694T2 (de) 2001-10-19 2008-02-07 Toyama Chemical Co. Ltd. Alkyletherderivate oder deren salze
EP2389937B1 (en) 2002-06-14 2018-08-15 Toyama Chemical Co., Ltd. Medicinal composition for improving brain function
CA2600381C (en) * 2005-03-28 2013-11-12 Toyama Chemical Co., Ltd. Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propyl)azetidin-3-ol or salts thereof
AU2007279673B2 (en) * 2006-08-04 2012-04-19 Toyama Chemical Co., Ltd. Protein kinase C activity enhancer containing alkyl ether derivative or salt thereof
MX2010012787A (es) * 2008-05-28 2011-02-24 Toyama Chemical Co Ltd Nuevo derivado de oxido de benzotiofeno y sal del mismo.
CA2917628A1 (en) * 2013-09-12 2015-03-19 F. Hoffmann-La Roche Ag Indol-carboxamide derivatives
SMT202000395T1 (it) 2014-01-31 2020-09-10 Fujifilm Toyama Chemical Co Ltd Agente di potenziamento dell'effetto della riabilitazione dopo lesione di un nervo comprendente un derivato di alchiletere o un suo sale
US10238632B2 (en) 2015-06-11 2019-03-26 Fujifilm Toyama Chemical Co., Ltd. Sigma receptor-binding agent
CN108366989B (zh) * 2015-12-25 2020-11-03 富士胶片富山化学株式会社 含有1-(3-(2-(1-苯并噻吩-5-基-)乙氧基)丙基)氮杂环丁-3-醇或其盐的片剂
JP7176957B2 (ja) * 2016-12-28 2022-11-22 富士フイルム富山化学株式会社 外用組成物
US11660287B2 (en) 2017-06-02 2023-05-30 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
MX393052B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para prevenir o tratar atrofia cerebral.
EP3636262A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA
BR112019024983A2 (pt) 2017-06-02 2020-06-23 Fujifilm Toyama Chemical Co., Ltd. Agente para reduzir a quantidade de proteína b amiloide
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
JPH05284992A (ja) * 1992-04-14 1993-11-02 Sagami Chem Res Center 神経成長因子産生促進剤及びその製造法
GB9309749D0 (en) * 1993-05-12 1993-06-23 Boots Co Plc Therapeutic agents
JPH07285912A (ja) * 1994-04-19 1995-10-31 Asahi Chem Ind Co Ltd 新規化合物ａｍ５２２１
JP2733207B2 (ja) * 1995-05-18 1998-03-30 工業技術院長 繊維芽細胞成長因子キメラ蛋白質を含有する医薬組成物
WO1999031056A1 (en) * 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
IL129178A0 (en) * 1999-03-25 2000-02-17 Yeda Res & Dev Induction of nerve generation
US6797726B1 (en) * 1999-06-11 2004-09-28 Toyama Chemical Co., Ltd. N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
GB2367554A (en) * 2000-10-04 2002-04-10 Lilly Co Eli Pharmacologically active amines
US20040030131A1 (en) * 2000-10-04 2004-02-12 Martine Keenan Pharmaceutical compounds
JP4303435B2 (ja) * 2001-02-26 2009-07-29 富山化学工業株式会社 ミトコンドリア機能賦活剤
CA2452596C (en) * 2001-07-05 2010-12-21 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered heterocyclic compounds, their production and use
JP4357802B2 (ja) * 2001-07-05 2009-11-04 武田薬品工業株式会社 ベンゼン環縮合５員複素環式化合物、その製造法および用途
JP4905752B2 (ja) * 2001-07-24 2012-03-28 エスティー・ラボ株式会社 揮発性有機塩素化合物センサ
DE60220694T2 (de) * 2001-10-19 2008-02-07 Toyama Chemical Co. Ltd. Alkyletherderivate oder deren salze
JP4537011B2 (ja) * 2002-03-01 2010-09-01 武田薬品工業株式会社 抗うつ剤
EP2389937B1 (en) * 2002-06-14 2018-08-15 Toyama Chemical Co., Ltd. Medicinal composition for improving brain function
JP2004256428A (ja) * 2003-02-25 2004-09-16 Science Univ Of Tokyo 神経栄養因子様プリン系化合物含有作用剤
AU2004229283B2 (en) * 2003-04-17 2009-02-05 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
JP4715514B2 (ja) * 2003-10-03 2011-07-06 小野薬品工業株式会社 神経再生促進剤

Also Published As

Publication number Publication date
CN101432280B (zh) 2012-11-21
KR20080111131A (ko) 2008-12-22
CA2648898A1 (en) 2007-11-08
CN101432280A (zh) 2009-05-13
JPWO2007125913A1 (ja) 2009-09-10
CA2648898C (en) 2015-01-20
EP2011796A1 (en) 2009-01-07
ZA200808728B (en) 2010-01-27
JP5695293B2 (ja) 2015-04-01
DK2011796T3 (da) 2014-10-27
EP2011796A4 (en) 2010-07-07
PT2011796E (pt) 2014-11-26
AU2007244409B2 (en) 2011-12-01
KR101374593B1 (ko) 2014-03-17
BRPI0710239A2 (pt) 2011-08-09
NZ571975A (en) 2011-04-29
AU2007244409A1 (en) 2007-11-08
EP2011796B1 (en) 2014-10-08
SI2011796T1 (sl) 2015-02-27
IL194569A0 (en) 2009-08-03
NO20084338L (no) 2008-11-19
JP2013177410A (ja) 2013-09-09
IL194569A (en) 2014-09-30
US20090093453A1 (en) 2009-04-09
WO2007125913A1 (ja) 2007-11-08
NO342153B1 (no) 2018-04-03
PL2011796T3 (pl) 2015-03-31
CY1115643T1 (el) 2017-01-04
ES2518371T3 (es) 2014-11-05

Similar Documents

Publication Publication Date Title
MX2008013728A (es) Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo.
MX2010002820A (es) Analogos de tiazolidindiona para tratamiento de hipertension.
TN2011000422A1 (en) Benzofuran derivatives
MX2008012399A (es) Modulacion de cinasa de ceramida.
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
MY144960A (en) Morpholine type cinnamide compound
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
WO2009156861A3 (en) Substituted pyrimidone derivatives
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
IL196754A0 (en) Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
TN2011000429A1 (en) Derivatives of benzothiazines, preparation thereof and application thereof as drugs
MY136824A (en) Substituted benzoxazinones and uses thereof
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
TW200719894A (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
UA86077C2 (en) Cetp inhibitors
SG165381A1 (en) Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors
EP1914229A4 (en) NOVEL CERCOSPORAMIDE DERIVATIVES
PL1904469T3 (pl) Nowe pochodne pirokatechiny
TW200700419A (en) 5,6-dialkyl-7-aminoazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds
AR040359A1 (es) Derivados de oxazol y su uso como sensibilizadores a la insulina

Legal Events

Date Code Title Description
FG Grant or registration